KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Twist Bioscience (TWST) Other Operating Expenses (2017 - 2026)

Twist Bioscience has reported Other Operating Expenses over the past 10 years, most recently at $53.6 million for Q1 2026.

  • Quarterly Other Operating Expenses rose 14.6% to $53.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $103.3 million through Mar 2026, up 11.53% year-over-year, with the annual reading at $5.9 million for FY2023, 58.49% down from the prior year.
  • Other Operating Expenses was $53.6 million for Q1 2026 at Twist Bioscience, up from $49.7 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $53.6 million in Q1 2026 and troughed at -$48.8 million in Q3 2025.
  • The 5-year median for Other Operating Expenses is $5.1 million (2022), against an average of $17.8 million.
  • Year-over-year, Other Operating Expenses skyrocketed 324.22% in 2022 and then tumbled 86.27% in 2023.
  • A 5-year view of Other Operating Expenses shows it stood at $4.1 million in 2022, then crashed by 85.95% to $581000.0 in 2023, then skyrocketed by 7795.52% to $45.9 million in 2024, then rose by 8.4% to $49.7 million in 2025, then increased by 7.78% to $53.6 million in 2026.
  • Per Business Quant, the three most recent readings for TWST's Other Operating Expenses are $53.6 million (Q1 2026), $49.7 million (Q4 2025), and -$48.8 million (Q3 2025).